Your browser doesn't support javascript.
loading
Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
Niemann, Carsten U; Munir, Talha; Moreno, Carol; Owen, Carolyn; Follows, George A; Benjamini, Ohad; Janssens, Ann; Levin, Mark-David; Robak, Tadeusz; Simkovic, Martin; Voloshin, Sergey; Vorobyev, Vladimir; Yagci, Munci; Ysebaert, Loic; Qi, Keqin; Qi, Qianya; Sinet, Pierre; Parisi, Lori; Srinivasan, Srimathi; Schuier, Natasha; Baeten, Kurt; Howes, Angela; Caces, Donne Bennett; Kater, Arnon P.
Afiliación
  • Niemann CU; Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. Electronic address: carsten.utoft.niemann@regionh.dk.
  • Munir T; St James's Hospital, Leeds, UK.
  • Moreno C; Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Josep Carreras Leukaemia Research Institute, Barcelona, Spain.
  • Owen C; Tom Baker Cancer Centre, Calgary, AB, Canada.
  • Follows GA; Addenbrookes Hospital, Cambridge, UK.
  • Benjamini O; Sheba Medical Center, Ramat Gan, Israel.
  • Janssens A; UZ Leuven Gasthuisberg, Leuven, Belgium.
  • Levin MD; Albert Schweitzer Hospital, Dordrecht, Netherlands.
  • Robak T; Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland.
  • Simkovic M; 4th Department of Internal Medicine-Haematology, Faculty of Medicine in Hradec Králové, University Hospital and Charles University in Prague, Hradec Králové, Czech Republic.
  • Voloshin S; Russian Scientific and Research Institute of Hematology and Transfusiology, St Petersburg, Russia.
  • Vorobyev V; SP Botkin Moscow City Clinical Hospital, Moscow, Russia.
  • Yagci M; Gazi Universitesi Tip Fakultesi, Ankara, Türkiye.
  • Ysebaert L; Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France.
  • Qi K; Janssen Research & Development, Titusville, NJ, USA.
  • Qi Q; Janssen Research & Development, Raritan, NJ, USA.
  • Sinet P; Janssen Research & Development, Bridgewater, NJ, USA.
  • Parisi L; Janssen Research & Development, Raritan, NJ, USA.
  • Srinivasan S; Oncology Translational Research, Janssen Research & Development, Lower Gwynedd Township, PA, USA.
  • Schuier N; Janssen Research & Development, Raritan, NJ, USA.
  • Baeten K; Janssen Research & Development, Beerse, Belgium.
  • Howes A; Janssen Research & Development, High Wycombe, UK.
  • Caces DB; Janssen Research & Development, Raritan, NJ, USA.
  • Kater AP; Amsterdam University Medical Centers, Cancer Center Amsterdam, University of Amsterdam, Amsterdam, Netherlands.
Lancet Oncol ; 24(12): 1423-1433, 2023 Dec.
Article en En | MEDLINE | ID: mdl-37944541
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neumonía / Leucemia Linfocítica Crónica de Células B Límite: Female / Humans / Male Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neumonía / Leucemia Linfocítica Crónica de Células B Límite: Female / Humans / Male Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article